Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-312024-12-31falseNursing Home282024-01-0131falsetruefalse 2783453 2024-01-01 2024-12-31 2783453 2023-01-01 2023-12-31 2783453 2024-12-31 2783453 2023-12-31 2783453 2023-01-01 2783453 c:Director2 2024-01-01 2024-12-31 2783453 d:Buildings 2024-01-01 2024-12-31 2783453 d:Buildings 2024-12-31 2783453 d:Buildings 2023-12-31 2783453 d:Buildings d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 2783453 d:PlantMachinery 2024-01-01 2024-12-31 2783453 d:PlantMachinery 2024-12-31 2783453 d:PlantMachinery 2023-12-31 2783453 d:PlantMachinery d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 2783453 d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 2783453 d:CurrentFinancialInstruments 2024-12-31 2783453 d:CurrentFinancialInstruments 2023-12-31 2783453 d:Non-currentFinancialInstruments 2024-12-31 2783453 d:Non-currentFinancialInstruments 2023-12-31 2783453 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 2783453 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 2783453 d:Non-currentFinancialInstruments d:AfterOneYear 2024-12-31 2783453 d:Non-currentFinancialInstruments d:AfterOneYear 2023-12-31 2783453 d:ShareCapital 2024-01-01 2024-12-31 2783453 d:ShareCapital 2024-12-31 2783453 d:ShareCapital 2023-01-01 2023-12-31 2783453 d:ShareCapital 2023-12-31 2783453 d:ShareCapital 2023-01-01 2783453 d:RevaluationReserve 2024-01-01 2024-12-31 2783453 d:RevaluationReserve 2024-12-31 2783453 d:RevaluationReserve 2023-01-01 2023-12-31 2783453 d:RevaluationReserve 2023-12-31 2783453 d:RevaluationReserve 2023-01-01 2783453 d:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 2783453 d:RetainedEarningsAccumulatedLosses 2024-12-31 2783453 d:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 2783453 d:RetainedEarningsAccumulatedLosses 2023-12-31 2783453 d:RetainedEarningsAccumulatedLosses 2023-01-01 2783453 c:FRS102 2024-01-01 2024-12-31 2783453 c:Audited 2024-01-01 2024-12-31 2783453 c:FullAccounts 2024-01-01 2024-12-31 2783453 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 2783453 c:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 2783453 d:AcceleratedTaxDepreciationDeferredTax 2024-12-31 2783453 d:AcceleratedTaxDepreciationDeferredTax 2023-12-31 2783453 5 2024-01-01 2024-12-31 2783453 6 2024-01-01 2024-12-31 2783453 e:PoundSterling 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure

Registered number: 2783453









JESYEM MEDICARE LIMITED









FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2024

 
JESYEM MEDICARE LIMITED
2783453

BALANCE SHEET
AS AT 31 DECEMBER 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 4 
3,046,287
3,044,673

Investments
 5 
172,138
167,113

  
3,218,425
3,211,786

Current assets
  

Debtors: amounts falling due within one year
 6 
432,489
442,560

Cash at bank and in hand
  
7,167
7,167

  
439,656
449,727

Creditors: amounts falling due within one year
 7 
(566,616)
(557,060)

Net current liabilities
  
 
 
(126,960)
 
 
(107,333)

Total assets less current liabilities
  
3,091,465
3,104,453

Creditors: amounts falling due after more than one year
 8 
(852,253)
(915,009)

Provisions for liabilities
  

Deferred tax
 9 
(9,885)
(9,481)

  
 
 
(9,885)
 
 
(9,481)

Net assets
  
2,229,327
2,179,963


Capital and reserves
  

Called up share capital 
  
1,000,000
1,000,000

Revaluation reserve
  
429,537
429,537

Profit and loss account
  
799,790
750,426

  
2,229,327
2,179,963


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 23 December 2025.



Page 1

 
JESYEM MEDICARE LIMITED
2783453
    
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024

E M Kumar
Director

The notes on pages 5 to 11 form part of these financial statements.

Page 2

 
JESYEM MEDICARE LIMITED
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024


Called up share capital
Revaluation reserve
Profit and loss account
Total equity

£
£
£
£

At 1 January 2024
1,000,000
429,537
750,426
2,179,963


Comprehensive income for the year

Profit for the year

-
-
49,364
49,364


Other comprehensive income for the year
-
-
-
-


Total comprehensive income for the year
-
-
49,364
49,364


Total transactions with owners
-
-
-
-


At 31 December 2024
1,000,000
429,537
799,790
2,229,327


The notes on pages 5 to 11 form part of these financial statements.

Page 3

 
JESYEM MEDICARE LIMITED
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2023


Called up share capital
Revaluation reserve
Profit and loss account
Total equity

£
£
£
£

At 1 January 2023
1,000,000
429,537
725,429
2,154,966


Comprehensive income for the year

Profit for the year

-
-
75,737
75,737


Other comprehensive income for the year
-
-
-
-


Total comprehensive income for the year
-
-
75,737
75,737


Contributions by and distributions to owners

Dividends: Equity capital
-
-
(50,740)
(50,740)


Total transactions with owners
-
-
(50,740)
(50,740)


At 31 December 2023
1,000,000
429,537
750,426
2,179,963


The notes on pages 5 to 11 form part of these financial statements.

Page 4

 
JESYEM MEDICARE LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1.


General information

Jesyem Medicare Limited is a company incorporated in the United Kingdom under the Companies Act. The company is a private company limited by shares and is registered in England and Wales. The address of the registered office is 19 Penrhyn Road, Kingston Upon Thames, Surrey, KT1 2BZ.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the requirements and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Going concern

The financial statements are prepared on a going concern basis.

The directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. As a result, they continue to adopt the going concern basis of accounting in preparing the financial statements.

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.4

Government grants

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.

Grants of a revenue nature are recognised in the Statement of comprehensive income in the same period as the related expenditure.

Page 5

 
JESYEM MEDICARE LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.5

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.6

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

 
2.7

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the Company in independently administered funds.

 
2.8

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Page 6

 
JESYEM MEDICARE LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.9

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Plant and machinery
-
15% per annum

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

The company's freehold buildings are not depreciated. The directors are of the opinion that the ongoing maintenance work undertaken keeps the properties to a high standard of repair. The directors also believe the residual value of the properties will remain not materially different from the value at which the properties are shown in the financial statements. For these reasons any provision for depreciation would be immaterial in the context of the company's financial statements.

 
2.10

Revaluation of tangible fixed assets

Individual freehold and leasehold properties are carried at current year value at fair value at the date of the revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. Revaluations are undertaken with sufficient regularity to ensure the carrying amount does not differ materially from that which would be determined using fair value at the balance sheet date.

Fair values are determined from market based evidence normally undertaken by professionally qualified valuers.

Revaluation gains and losses are recognised in other comprehensive income unless losses exceed the previously recognised gains or reflect a clear consumption of economic benefits, in which case the excess losses are recognised in profit or loss.

 
2.11

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

 
2.12

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Page 7

 
JESYEM MEDICARE LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.13

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.14

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 28 (2023 - 31).


4.


Tangible fixed assets


Freehold property
Plant and machinery
Total

£
£
£



Cost or valuation


At 1 January 2024
3,000,000
451,494
3,451,494


Additions
-
11,814
11,814



At 31 December 2024

3,000,000
463,308
3,463,308



Depreciation


At 1 January 2024
-
406,821
406,821


Charge for the year on owned assets
-
10,200
10,200



At 31 December 2024

-
417,021
417,021



Net book value



At 31 December 2024
3,000,000
46,287
3,046,287



At 31 December 2023
3,000,000
44,673
3,044,673

The property was revalued on 10 January 2022 by Copping Joyce, a firm of chartered surveyors and valuers, on an open market value for existing use basis at £3,000,000, which the directors believe is representative of the property value as at 31 December 2022. If the property above were disposed of at open market value, the tax liability is estimated at £Nil. 

Page 8

 
JESYEM MEDICARE LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

           4.Tangible fixed assets (continued)

If the land and buildings had not been included at valuation they would have been included under the historical cost convention as follows:

2024
2023
£
£



Cost
1,792,572
1,792,572

Net book value
1,792,572
1,792,572


5.


Fixed asset investments





Investments in subsidiary companies

£



Cost or valuation


At 1 January 2024
167,113


Additions
5,025



At 31 December 2024
172,138





6.


Debtors

2024
2023
£
£


Trade debtors
169,030
150,941

Amounts owed by group undertakings
242,870
248,051

Other debtors
20,589
43,568

432,489
442,560


Page 9

 
JESYEM MEDICARE LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

7.


Creditors: Amounts falling due within one year

2024
2023
£
£

Bank overdrafts
45,601
16,551

Bank loans
60,874
54,750

Trade creditors
151,870
182,782

Amounts owed to group undertakings
205,113
205,113

Corporation tax
37,619
22,769

Other taxation and social security
-
11,152

Other creditors
30,429
15,220

Accruals and deferred income
35,110
48,723

566,616
557,060



8.


Creditors: Amounts falling due after more than one year

2024
2023
£
£

Bank loans
852,253
910,042

Other creditors
-
4,967

852,253
915,009


The following liabilities were secured:




Details of security provided:

Bank loans and overdraft totaling £958,728 (2023: £981,344) are secured over the assets of the company. The bank loans are secured by way of a fixed and floating charge over the undertaking and all property and assets.


9.


Deferred taxation




2024


£






At beginning of year
(9,481)


Charged to profit or loss
(404)



At end of year
(9,885)

Page 10

 
JESYEM MEDICARE LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
 
9.Deferred taxation (continued)

The provision for deferred taxation is made up as follows:

2024
2023
£
£


Accelerated capital allowances
(9,884)
(9,481)

(9,884)
(9,481)


10.


Related party transactions

The company owns a freehold investment property but has has granted rights over the property to Limje Industrial Limited, a fellow subsidiary and accordingly, the directors feel that it is appropriate to show the asset and the related income and costs in the accounts of Limje Industrial Limited.


11.


Controlling party

The directors consider the ultimate parent undertaking to be Limje Holdings Limited, a company which is registered in England and Wales. The registered office is 11-13 Grove Road, Sutton, Surrey, England, SM1 1DS


12.


Auditors' information

The auditors' report on the financial statements for the year ended 31 December 2024 was unqualified.

The audit report was signed on 23 December 2025 by Robert Carter (Senior statutory auditor) on behalf of Feltons.

Page 11